Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

CMS Plan To Remove Speaker Payment Disclosure Exemption: Stigmatizing Or Administrative?

This article was originally published in The Gray Sheet

Executive Summary

A proposal by CMS to remove an explicit exemption from Open Payments/Sunshine Act disclosure requirements for certain continuing medical education speakers will unnecessarily stigmatize physicians, says a CME industry group, but CMS and others suggest the proposed change will not have much, if any, practical impact on physicians or companies.

You may also be interested in...



CME Programs Endure As Industry Funding, Number Of Providers Declines

Accreditation Council for Continuing Medical Education reports that commercial support for CME activities declined in 2011 but the number of activities increased 3.8%; more than 20 million participated in CME programs.

Puberty Blockers: FDA's Califf Asked If REMS, Boxed Warning Against Off-Label Use In The Works

FDA Commissioner Robert Califf tells House appropriations subcommittee chair the agency will 'consider any information that may be available' on off-label use of puberty blockers for gender dysphoria before making a regulatory decision.

ADHD Drugs: FDA Commissioner Blames Inappropriate Prescribing For Shortages

ADHD drug shortages may have resulted from industry reticence to fill DEA quotas, as well as a 'heavy element of professional responsibility' with off-label prescribing, Robert Califf told a House appropriations subcommittee.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT033138

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel